Tern updates on portfolio company Device Authority

Tern plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, has announced an update in relation to Device Authority Limited, a company in which Tern has a 30.0% equity holding.

The remaining Tranche Two of the Device Authority Fundraising of US$3.3 million, by Ten Eleven Ventures was, as announced on 27 December 2023, due to be completed on or prior to 30 September 2024.  Due to the positive current performance of Device Authority, it has been agreed by the Device Authority board to defer the completion of Tranche Two to, if required, on or before 31 December 2024.

Tern’s holding in Device Authority therefore remains unchanged at 30.0% (before any dilution on exercise of share options or the potential completion of Tranche Two), with this holding having an unaudited book valuation of approximately US$5.4 million (approximately £4.2 million), as announced on 9 August 2024.

Unless otherwise stated, defined terms should be given the meaning given to them in the Company’s announcement made on 27 December 2023.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Tern Plc Extends Convertible Loan Maturities in Talking Medicines to Strengthen Exit Strategy

Tern Plc extends all convertible loan maturities in Talking Medicines to 2029, enhancing its strategic position for future exit.

A new frontier for medical device trust and patient safety

Connected medical device risk is rising and a platform that automates identity, credential and data‑protection lifecycles may become an infrastructure segment worth watching.

When HCP Dialogue Becomes Quantifiable Intelligence

Talking Medicines’ DrugVoice platform turns real‑world HCP dialogue into measurable insight, letting brand‑teams forecast message resonance before launch.

Immersive cardiac training tech gaining ground in high-stakes procedures

Immersive simulation platforms like Fundamental XR are shaping the infrastructure behind safer, faster adoption of intracardiac procedures.

Search

Search